MAIA Biotechnology, Inc.

AMEX:MAIA

Biotechnology

Healthcare
$1.30 +3.41%

+$0.05 today

Market cap
$80.28M
Beta
0.24
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.87High $3.19

Volume 2.25M

Average 0.78M

MAIA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

MAIA Biotechnology, Inc.AMEX: MAIA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 32.12M shares rose 16.0% year over year, behind the +27.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +51.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +16.0% toward the trailing-twelve-month pace of +27.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
32.12M+0.0% QoQ
Last fiscal yearDec 2025
32.12M+44.7% YoY
LTMMar 2026
31.93M+27.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.0%——
1 year+44.7%——
3-year CAGR+51.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
32.12M USD
Year-over-year change
+44.7%
4-year CAGR
+31.8%

Weighted Avg Shares (Diluted) vs competitors

How MAIA compares with its peers on the latest reported figures

  • MAIA's LTM Mar 2026 weighted avg shares (diluted) of 31.93M shares is the 2nd highest of the 7 companies compared; the peer median is 20.9M shares.
  • Its year-over-year change of +27.8% is the 4th highest of 7, against a peer median of +32.3%.
  • Over three fiscal years its annual growth of +51.3% compares with a peer median of +23.6%.
MAIA Competitors Peer median
Weighted Avg Shares (Diluted) for MAIA and competitors
Company Period LTM YoY 3-year CAGR
RNXTRenovoRx, Inc.LTM Mar 202636.65M +42.8%+25.0%
MAIAMAIA Biotechnology, Inc.LTM Mar 202631.93M +27.8%+51.3%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+19.5%
ANVSAnnovis Bio, Inc.LTM Mar 202622.96M +82.5%+36.0%
PYPDPolyPid Ltd.LTM Mar 202618.85M +145.8%+132.9%
VERUVeru Inc.LTM Mar 202617.82M +21.7%+22.3%
LTRNLantern Pharma Inc.LTM Mar 202610.94M +1.6%+0.1%
Peer median (excluding MAIA) 20.9M+32.3%+23.6%

Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.45M8.93M11.11M10.01M14.55B
Selling, General & Admin4.29M6.14M9.07M6.95M9.72B
Operating Expenses7.79M16.18M20.18M16.96M24.27M
Depreciation & Amortization00000
EBITDA(11.75M)(15.76M)(19.77M)(23.25M)(22.4M)
EBITDA Margin—————
Operating Income(7.79M)(16.18M)(20.18M)(16.96M)(24.27M)
Operating Margin—————
Interest Income2.01K1.87K27.63K318.37K313.95K
Interest Expense827.54K6.97K0570
Other Income / Expenses(4.79M)406.92K409.48K(6.3M)1.87M
Income Before Tax(12.58M)(15.77M)(19.77M)(23.25M)(22.4M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(12.5M)(15.77M)(19.77M)(23.25M)(22.4M)
Net Margin—————
EPS (Basic)(1.18)(1.70)(1.49)(1.05)(0.70)
EPS (Diluted)(1.18)(1.70)(1.49)(1.05)(0.70)
Weighted Avg Shares10.64M9.28M13.26M22.2M32.12M
Weighted Avg Shares (Diluted)10.64M9.28M13.26M22.2M32.12M

MAIA Biotechnology, Inc.

AMEX:MAIA

Intrinsic Alpha fair value

Locked

Current Price

$1.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.